1Li G, Hu Y,Yang W, et al. Effects of insulin resistance and insulin secretionon the efficacy of intervention to retard development of type 2 diabetes mellitus:the DA Qing IGT and Diabetes Study [ J]. Diabetes Res Clin Pract,2002 ;58 ( 3 ) : 193.
3Kitaoka H. Efficacy of combination therapy of alpha-glucosidase inhibitor and insulin sensitizer in patients with type 2 diabetes[J]. Nippon Rinsho ,2002 ;60 ( Suppl 9 ) :464.
4Edelstein SL, Knowler WC, Bain BP, et al. Predictors of progression from impaired glucose tolerance to NIDDM : an analysis of six prospective studies[ J]. Diabetes, 1997 ;46 (4) :701.
5Haffner SM. Can reducing peaks prevent type 2 diabetes: implication from recent diabetes prevention trials [ J ]. Int J Clin Pract Suppl, 2002 ; 129:33.
1Defronzo RA, Ferrannini E, Simensen DC. Fasting hyperglycemia in non-insulin-dependent diabetes mellitus, contributions of excessive hepatic glucose production and impaired tissue glucose uptake. Metabolism, 1989,38:387-395.
2Pimenta W, Korytkowski M, Mitrakou A, et al. Pancreatic β-cell dysfuction as the primary genetic lesion in NIDDM: evidence from studies in normal glucose-tolerant individuals with a first-degree NIDDM relative. JAMA, 1995, 273:1855-1861.
3Melchionda N, Forlani G, Marchesini G, et al. WHO and ADA criteria for the diagnosis of diabetes mellitus in relation to body mass index. Insulin sensitivity and secretion in resulting subcategories of glucose tolerance. Int J Obes Relat Metab Disord,2002,26: 90-96.
4Li CL, Tsai ST, Chou P. Comparison of metabolic risk profiles between subjects with fasting and 2-hour plasma glucose impairment: The Kinmen Study. J Clin Epidemiol,2002,55: 19-24.
5Gomez-Perez FJ, Aguilar-Salinas CA, Lopes-Alvarenga JC, et al. Lack of agreement between the World Health Organization category of impaired glucose tolerance and the American Diabetes Association category of impaired fasting glucose. Diabetes Care, 1998, 21:1886-1888.
6Davies MJ, Raymond NT, Day JL, et al. Impaired glucose tolerance and fasting hyperglycaemia have different characteristics. Diabet Med, 2000, 17:433-440.
3CHIASSON J L. Acarbose for the prevention of diabetes, hypertension, and cardiovascular disease in subjects with impaired glucose tolerance: the Study to Prevent Non-In- sulin-Dependent Diabetes Mellitus (STOP-NIDDM) Trial [J]. Endocr Pract, 2006, 12 (Suppl 1): 25-30.
4HANEFELD M, SCHAPER F, KOEHLER C. Effect of acarbose on vascular disease in patients with abnormal glucose tolerance[ J]. Cardiovasc Drugs Ther, 2008, 22 (3) : 225-231.
5ZEYMER U. Cardiovascular benefits of acarbose in im- paired glucose tolerance and type 2 diabetes [ J ]. Int J Cardiol. 2006, 107 (1): 11-20.
6Shinde J,Taldone T,Barletta M,et al.α-Glucosidase inhibitory activity of Syzygium cumini(Linn).Skeels seed kernel in vitro and in Goto-Kakizaki(GK)rats[J].Carbohydr Res,2008,343(7):1278-l281.
8Lysek R,Schutz C,Favre S,et al.Search forα-glueosidase inhibitors:New N-substituted valienamine and conduramine F-1 derivatives[J].Bioorg Med Chem,2006,14(18):6255-6282.
9Augustin LA,Fantini J,Mootoo DR.C-glycoside analogues of beta-galactosylceramide with a simple ceramide substitute:synthesis and binding to HIV-1 gpl20[J].Bioorg Med Chem,2006,14(4):1182-1188.
10Garg H,Franeella N,Tony K A,et al.Glycoside analogs ofβ-galactosylceramide,a novel class of small molecule antiviral agents that inhibit HIV-1 entry[J].Antiviral Res,2008,80(1):54-61.
